(PRESS RELEASE) AMSTERDAM, 26-Jun-2020 — /EuropaWire/ — The global leader in health technology Royal Philips (NYSE: PHG, AEX: PHIA) has announced the four-year results from the ILLUMENATE European Randomized Controlled Trial (EU RCT). New data from the EU RCT reconfirms … Read the full press release
Posted in Healthcare, Netherlands, News, Pharma & Biotech, Science, Technology
Tagged Chris Landon, EU RCT, health technology, ILLUMENATE European Randomized Controlled Trial, ILLUMENATE Pivotal trial, Marianne Brodmann MD, percutaneous transluminal angioplasty, peripheral arterial disease, Philips EnduraCoat technology, Philips’ Stellarex low-dose Drug-Coated Balloon, polyethylene glycol, PTA, RCT, Royal Philips, Stellarex DCB, Vascular Interventional Advances, VIVA, William Gray MD
First Presentation of Results from Regional Cohorts of IN.PACT Global Study Reinforce Strong, Consistent and Safe Outcomes for PAD Patients DUBLIN and LEIPZIG, 25-Jan-2017 — /EuropaWire/ — Medtronic today presented new data at the Leipzig Interventional Course (LINC) 2017 conference supporting … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
